Table 12.
Sensitivity of macrolides and structurally related agents against key causative organisms in bacterial vaginosis
| Study (year) | Country | Year(s) |
Minimum inhibitory concentrations of specific macrolides (µg/ml)
|
Ref. | |||||
|---|---|---|---|---|---|---|---|---|---|
| Azithromycin | Erythromycin | Clarithromycin | Roxithromycin | Clindamycin † | Telithromycin † | ||||
| Gardnerella vaginalis | |||||||||
| Jones et al. (1998) | UK | NR | <0.03–0.125 | <0.03–0.06 | NR | NR | NR | NR | [201] |
| Shanker et al. (1982) | Australia | NR | NR | 0.007–0.06 | NR | NR | 0.007–0.06 | NR | [202] |
| King † et al. (1987) | NR | NR | 0.008–0.016 | NR | 0.016 | NR | NR | [203] | |
| Bacteroides species | |||||||||
| Jones et al. (1998) | UK | NR | 0.06 –16 | <0.03–32 | NR | NR | NR | NR | [201] |
| Dubreuil et al. (1987) | England, France, Germany, Japan | NR | NR | 0.003–>64 | NR | 0.003–>64 | NR | NR | [204] |
| Maskell et al. (1990) | UK | NR | 0.5–>16 | <0.25–16 | NR | NR | NR | NR | [205] |
| Chang et al. (1995) | Taiwan | 1989–1992 | 1–>256 | 0.25–>256 | ≤0.03–>256 | 0.25–>256 | NR | NR | [206] |
| Ednie et al. (1997) | USA | NR | 1–>64 | 0.5–>64 | 0.5–>64 | 2–>64 | ≤0.06–>64 | NR | [207] |
| Mikamo et al. (2003) | Japan | 2000 | 0.125– 32 | 0.125–32 | 0.063 to16 | NR | NR | 0.032–16 | [208] |
| Marina et al. (2009) | Bulgaria | 1983–2007 | NR | 0.5–>64 | NR | NR | 0.125–32 | NR | [209] |
| Chen et al. (1992) | Australia | 1986–1991 | 0.5 to128 | 0.25–128 | NR | NR | NR | NR | [210] |
| Wexler et al. (2001) | USA | NR | NR | NR | NR | NR | 0.25–>64 | [211] | |
| Mycoplasma hominis | |||||||||
| Ridgway et al. (1987) | UK | NR | NR | >32 | NR | 8 to16 | NR | NR | [203] |
| Mobinculus species | |||||||||
| Spiegel et al. (1987) | USA | NR | NR | ≤0.2–>200 | NR | NR | ≤0.015–4 | NR | [212] |
Unspecified low-risk population.
†
Not a macrolide but has similar mechanism of action and included for comparability.
NR: Not reported.